Oral dual GLP-1/GIP obesity data + 14 more major updates...👇
🎯 → Approvals
🔬 → New data
🤝 → M&A activity
Merck
🎯 FDA approved WINREVAIR™ (sotatercept-csrk) treating adults with pulmonary arterial hypertension.
🎯 EC approved KEYTRUDA® (pembrolizumab) + chemotherapy as neoadjuvant Treatment, then continued as monotherapy as adjuvant treatment NSCLC.
Akebia
🎯 Received FDA approval for Vafseo® (vadadustat) for the treatment of anemia due to CKD in adult patients on dialysis.
Endo International
🎯 Received approval in Canada for WAKIX® (pitolisant hydrochloride tablets) for use in pediatric patients.
Amneal Pharmaceuticals, Inc.
🎯 FDA Approved Ciprofloxacin and Dexamethasone otic suspension for the treatment of infections.
Esperion Therapeutics
🎯 Received FDA approved for broad new labels for NEXLETOL® and NEXLIZET® to prevent heart attacks and cardiovascular procedures.
AstraZeneca
🎯 FDA approved Ultomiris treating NMOSD.
🎯 Beyfortus received approval in Japan for the prevention of RSV disease in infants, and Truqap + Faslodex treating advanced HR-positive breast cancer.
Zevra Therapeutics
🔬 Topline data reported from the Ph2 trial of KP1077 for idiopathic hypersomnia.
Viking Therapeutics
🔬 Reported results from the Ph1 trial of oral tablet formulation of dual GLP-1/GIP receptor agonist VK2735.
Inozyme Pharma
🔬 Report topline data on Apr. 8, 2024 for the Ph1/2 trials of INZ-701.
Sellas Life Sciences
🔬 Topline data reported from the Ph2a trial of SLS009 in r/r AML.
Ceapro & Aeterna Zentaris
🤝 Received final court approval for merger with Aeterna Zentaris.
Avalo Therapeutics & AlmataBio
🤝 Announced the acquisition of AlmataBio.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
March 25-29, 2024
Article History:
RF, DV (03/29/24)
Comments